A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria

Trial Identifier: AZ-RU-00010
Sponsor: AstraZeneca
Start Date: May 2025
Primary Completion Date: July 2026
Study Completion Date: July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
RU Aramil, RU, 624002
RU Izhevsk, RU, 426061
RU Moscow, RU, 117036
RU Moscow, RU, 111539
RU Moscow, RU, 129327
RU Perm, RU, 614000
RU Saratov, RU, 410054
RU Saratov, RU, 410053
RU St Petersburg, RU, 195067
RU Yaroslavl, RU, 150062